Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Dec 11;41(12):2007-2010.
doi: 10.1016/j.ccell.2023.10.002. Epub 2023 Oct 26.

Bringing CAR T cell therapy trials to underserved populations

Hoda Badr  1 , Rayne Rouce  2 , Michael E Scheurer  3 , Premal Lulla  4 , Martha Mims  4 , Pavan Reddy  5
Affiliations

Bringing CAR T cell therapy trials to underserved populations

Hoda Badr et al. Cancer Cell. .

Abstract

There is a critical need for equitable access to cell therapies in cancer treatment, particularly within public safety-net healthcare systems that serve minority and socioeconomically disadvantaged populations. We discuss how the Dan L Duncan Comprehensive Cancer Center at Baylor College of Medicine is piloting a cell therapy program aimed at addressing cancer care disparities and has the potential to serve as a national model for enhancing health equity in cancer care.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests The authors declare no competing interests.

Figures

Figure 1.
Figure 1.
The Dan L Duncan Comprehensive Cancer Center approach to enhancing equitable access to cell therapies
See this image and copyright information in PMC

References

    1. Fact Sheet: White House Announces Initial Steps for Reignited Cancer Moonshot. (2022). https://www.whitehouse.gov/ostp/news-updates/2022/03/17/fact-sheet-white....
    1. American Cancer Society (2021). Cancer Facts and Figures. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-....
    1. Loree JM, Anand S, Dasari A, Unger JM, Gothwal A, Ellis LM, Varadhachary G, Kopetz S, Overman MJ, and Raghav K (2019). Disparity of Race Reporting and Representation in Clinical Trials Leading to Cancer Drug Approvals From 2008 to 2018. JAMA Oncology 5, e191870–e191870. 10.1001/jamaoncol.2019.1870. - DOI - PMC - PubMed
    1. Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, Braunschweig I, Oluwole OO, Siddiqi T, Lin Y, et al. (2017). Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma. N Engl J Med 377, 2531–2544. 10.1056/NEJMoa1707447. - DOI - PMC - PubMed
    1. Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jäger U, Jaglowski S, Andreadis C, and Westin JR (2019). Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N. Engl. J. Med. 380, 45–56. - PubMed

Publication types

LinkOut - more resources